Treats severe diarrhea and flushing episodes associated with metastatic carcinoid tumors. ANDA 210317, held by Teva Pharms USA Inc. Octreotide Acetate.
As of Nov 16, 2026, ANDA 210317 (Octreotide Acetate), held by Teva Pharms USA Inc, was first approved by FDA on Dec 5, 2023, with 0 approved supplements and 0 published complete response letters.
Octreotide acetate for injectable suspension 10 mg, 20 mg, and 30 mg is indicated in patients in whom initial treatment with octreotide acetate injection has been shown to be effective and tolerated. Octreotide acetate for injectable suspension is a somatostatin analogue indicated for: Treatment in patients who have responded to and tolerated octreotide acetate injection subcutaneous injection for: Acromegaly Severe diarrhea/flushing episodes associated with metastatic carcinoid tumors Profuse watery diarrhea associated with Vasoactive Intestinal Peptide (VIP) secreting tumors 1.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 5, 2023 | Original application | Approved | None posted |
| Octreotide AcetateEQ 10MG BASE/VIAL · injectable;injection | Octreotide Acetate | Rx |
| Octreotide AcetateEQ 20MG BASE/VIAL · injectable;injection | Octreotide Acetate | Rx |
| Octreotide AcetateEQ 30MG BASE/VIAL · injectable;injection | Octreotide Acetate | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters